FDA of­fi­cials, ex­perts dis­cuss im­pact of Covid-19 on cell and gene ther­a­pies

While the FDA is still re­ceiv­ing in­ves­ti­ga­tion­al new drug ap­pli­ca­tions (INDs) for cell and gene ther­a­pies, of­fi­cials are con­cerned about the im­pact of the Covid-19 pan­dem­ic on clin­i­cal tri­als.

Pe­ter Marks

“It’s clear that COVID-19 has ad­verse­ly af­fect­ed all as­pects of de­vel­op­ment of cell and gene ther­a­pies,” said CBER di­rec­tor Pe­ter Marks at the Al­liance for Re­gen­er­a­tive Med­i­cine’s Meet­ing on the Mesa. “For some of the stud­ies that are on­go­ing there are some re­al chal­lenges to over­come in terms of end­points that may have been missed.”

The pan­dem­ic al­so has dis­rupt­ed glob­al har­mo­niza­tion ef­forts around gene ther­a­pies, Marks said.

“We were on the cusp, in fact, work­ing with glob­al reg­u­la­tors try­ing to get to­wards more har­mo­niza­tion of gene ther­a­py pro­grams in dif­fer­ent coun­tries,” he said. “We’re try­ing to keep it mov­ing but it’s a chal­lenge to do.”

Marks not­ed that be­fore Covid-19 he spent about 75% of his time on cell and gene ther­a­pies, but the pan­dem­ic has forced him to shift pri­or­i­ties. “Some things have less pol­i­cy de­mands at this point in time. At this point in time it’s very much re­versed and it’s prob­a­bly 80% of my time on COVID-re­lat­ed ac­tiv­i­ties.”

Marks al­so not­ed that CBER’s Of­fice of Tis­sues and Ad­vanced Ther­a­pies (OTAT) has been strug­gling to keep up with its work­load even be­fore the pan­dem­ic. With the in­flux of ap­pli­ca­tions for cell and gene ther­a­pies over the last five years, Marks said the of­fice, “Should have dou­bled in size and it’s on­ly mod­est­ly larg­er, 15-20% larg­er in size.”

Marks said he is not sat­is­fied with the lev­el of di­a­logue the agency has been able to have with gene ther­a­py de­vel­op­ers. “Es­pe­cial­ly ear­ly on, we should be able to have this di­a­logue that re­al­ly fa­cil­i­tates set­ting things up well so that our knowl­edge of the en­tire field—we help lever­age that for every spon­sor.”

“We’ve been so strapped in terms of per­son­nel that it’s hard to do that,” Marks said, not­ing that Covid-19 has ex­ac­er­bat­ed things even fur­ther. “Be­cause the num­ber of gene ther­a­py ap­pli­ca­tions hasn’t fall­en off dra­mat­i­cal­ly, some of the tri­als may not be mov­ing as quick­ly, but the ap­pli­ca­tions keep com­ing in.” Marks said that OTAT has al­so had to shift pri­or­i­ties dur­ing the pan­dem­ic and that he hopes the next user fee cy­cle will bring in the re­sources nec­es­sary to staff up fur­ther.

Wil­son Bryan

Speak­ing on a sep­a­rate pan­el with mem­bers of in­dus­try, OTAT Di­rec­tor Wil­son Bryan echoed Marks’ sen­ti­ment.

“We were stretched thin be­fore the pan­dem­ic, and with the flood of work that came in, it re­al­ly had an im­pact,” he said. “Some­times folks don’t like to ad­mit this, but we all know we’ve had de­layed meet­ings, we’ve had to de­lay re­view of some ap­pli­ca­tions be­cause of giv­ing pri­or­i­ty to the pan­dem­ic.”

How­ev­er, Bryan said the of­fice is get­ting its bal­ance and is work­ing to catch up on some of its de­layed ac­tiv­i­ties.

Bryan ex­pressed some wor­ry about the fi­nan­cial well-be­ing of some of the small­er com­pa­nies his of­fice works with. “We’re hear­ing a lot about their strug­gles to stay afloat and con­tin­ue and fin­ish off their de­vel­op­ment pro­grams and whether or not those de­vel­op­ment pro­grams are go­ing to be suf­fi­cient to meet reg­u­la­to­ry stan­dards,” he said.

One of the chal­lenges, said Tim­o­thy Schroed­er, CEO of CTI Clin­i­cal Tri­al & Con­sult­ing, will be deal­ing with gaps in da­ta from clin­i­cal tri­als. “The ques­tion is go­ing to be how do spon­sors, how do reg­u­la­to­ry au­thor­i­ties and how do com­pa­nies such as our­selves fill those gaps?”

On the reg­u­la­tor side, Bryan said his of­fice is work­ing with com­pa­nies on an in­di­vid­ual ba­sis to sort out those is­sues, which dif­fer from one in­di­ca­tion to the next.

Bryan added that one pos­i­tive to come of the pan­dem­ic is greater in­ter­est in re­mote out­come as­sess­ments in clin­i­cal tri­als. “If we have an en­er­gy now to de­vel­op out­come mea­sures and val­i­date out­come mea­sures that al­low us to re­li­ably cap­ture in­for­ma­tion from pa­tients in re­mote lo­ca­tions, that will ul­ti­mate­ly fa­cil­i­tate de­vel­op­ment,” he said.

The pan­dem­ic al­so has sig­nif­i­cant­ly dis­rupt­ed FDA’s abil­i­ty to con­duct sur­veil­lance and preap­proval in­spec­tions. While the agency has re­sumed some do­mes­tic in­spec­tions and mis­sion-crit­i­cal for­eign in­spec­tions, it al­so is lever­ag­ing oth­er sources of in­for­ma­tion, in­clud­ing in­spec­tion re­ports from oth­er reg­u­la­tors, and re­quest­ing doc­u­ments from ap­pli­cants and fa­cil­i­ties in lieu of on-site in­spec­tions where pos­si­ble.

“We’re con­sid­er­ing vir­tu­al in­spec­tions, par­tic­u­lar­ly for com­pa­nies where the site has a track record, but if it’s a site that is brand new with no track record or if it’s a site with that has a bad track record, we’re hes­i­tant to do that,” Bryan said.

Bryan al­so raised the prospect of FDA in­spec­tors tag­ging along re­mote­ly for an in­spec­tion be­ing con­duct­ed by oth­er reg­u­la­tors. “Is it pos­si­ble that we could have an in­spec­tion by Eu­ro­pean in­spec­tors and have US reg­u­la­tors go­ing along for a vir­tu­al in­spec­tion at the same time? We think about those things, I don’t know that we’ve done them yet,” Bryan said, adding that he is not sure whether FDA in­spec­tors would be com­fort­able with the in­for­ma­tion they would get.

Cur­ran Simp­son

Cur­ran Simp­son, chief op­er­a­tions and tech­nol­o­gy of­fi­cer at Re­genxbio, said he sees promise in vir­tu­al au­dits and be­lieves the lev­el of doc­u­men­ta­tion a site pro­vides can be in­dica­tive of its com­pli­ance.

“How of­ten have I walked in­to a man­u­fac­tur­ing fa­cil­i­ty that’s well-run but has ter­ri­ble doc­u­men­ta­tion? Al­most nev­er. I think vir­tu­al au­dits, if you do a risk-based ap­proach and the au­dit part­ner has the abil­i­ty to send doc­u­men­ta­tion in an ef­fi­cient way and you have ex­pe­ri­enced peo­ple do­ing this, I think you’re go­ing to get the same fla­vor of an au­dit very quick­ly from the lev­el of the doc­u­men­ta­tion,” he said.

“Of course, you’ll want to ac­com­pa­ny that to the ex­tent pos­si­ble with imag­ing of the fa­cil­i­ty,” Simp­son said, “To see if those prac­tices are be­ing fol­lowed, the over­all clean­li­ness of the fa­cil­i­ty and the man­age­ment of ma­te­r­i­al move­ment … If you don’t get a good im­pres­sion from the doc­u­men­ta­tion that you’re work­ing through, it’s prob­a­bly a big­ger is­sue that you want to es­ca­late.”

Amy DuRoss

Amy DuRoss, co-founder and CEO of Vineti, an en­ter­prise soft­ware com­pa­ny spe­cial­iz­ing in ad­vanced ther­a­pies, ex­pressed some doubts about the cur­rent po­ten­tial for ful­ly re­mote au­dits.

“Cer­tain­ly our piece of the chain be­cause we’re en­ter­prise soft­ware is read­i­ly au­ditable re­mote­ly, but I would say that the over­all sys­tem and in man­u­fac­tur­ing, I’m not sure we’ve evolved as a species yet to adapt our re­mote tech­niques to get a full pic­ture … I don’t think we’re there yet,” she said.


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Stephen Hahn, FDA commissioner (AP Images)

As FDA sets the stage for the first Covid-19 vac­cine EUAs, some big play­ers are ask­ing for a tweak of the guide­lines

Setting the stage for an extraordinary one-day meeting of the Vaccines and Related Biological Products Advisory Committee this Thursday, the FDA has cleared 2 experts of financial conflicts to help beef up the committee. And regulators went on to specify the safety, efficacy and CMC input they’re looking for on EUAs, before they move on to the full BLA approval process.

All of this has already been spelled out to the developers. But the devil is in the details, and it’s clear from the first round of posted responses that some of the top players — including J&J and Pfizer — would like some adjustments and added feedback. And on Thursday, the experts can offer their own thoughts on shaping the first OKs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.

Michel Vounatsos, Biogen CEO (via YouTube)

UP­DAT­ED: Bio­gen spot­lights a pair of painful pipeline set­backs as ad­u­canum­ab show­down looms at the FDA

Biogen has flagged a pair of setbacks in the pipeline, spotlighting the final failure for a one-time top MS prospect while scrapping a gene therapy for SMA after the IND was put on hold due to toxicity.

Both failures will raise the stakes even higher on aducanumab, the Alzheimer’s drug that Biogen is betting the ranch on, determined to pursue an FDA OK despite significant skepticism they can make it with mixed results and a reliance on post hoc data mining. And the failures are being reported as Biogen was forced to cut its profit forecast for 2020 as a generic rival started to erode their big franchise drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.

A new chap­ter in the de­cen­tral­ized clin­i­cal tri­al ap­proach

Despite the promised decentralized trial revolution, we haven’t yet moved the needle in a significant way, although we are seeing far bolder commitments to this as we continue to experience the pandemic restrictions for some time to come. The vision of grandeur is one thing, but operationalizing and execution are another and recognising that change, particularly mid-flight on studies, is worthy of thorough evaluation and consideration in order to achieve success. Here we will discuss one of the critical building blocks of a Decentralized and Remote Trial strategy: TeleConsent; more than paper under glass, it is a paradigm change and key digital enabler.

Pfizer CEO Albert Bourla (Drew Angerer/Getty Images)

Pfiz­er is on the verge of claim­ing a multi­bil­lion-dol­lar first-mover ad­van­tage with their Covid-19 vac­cine — an­a­lyst

From the beginning, Pfizer CEO Albert Bourla eschewed government funding for his Covid-19 vaccine work with BioNTech, willing to take all the $2 billion-plus risk of a lightning-fast development campaign in exchange for all the rewards that could fall its way with success. And now that the pharma giant has seized a solid lead in the race to the market, those rewards loom large.

SVB Leerink’s Geoff Porges has been running the numbers on Pfizer’s vaccine, the mRNA BNT162b2 program that the German biotech partnered on. And he sees a $3.5 billion peak in windfall revenue next year alone. Even after the pandemic is brought to heel, though, Porges sees a continuing blockbuster role for this vaccine as people around the world look to guard against a new, thoroughly endemic virus that will pose a permanent threat.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: CRISPR Ther­a­peu­tics gets a snap­shot of off-the-shelf CAR-T suc­cess in B-cell ma­lig­nan­cies — marred by the death of a pa­tient

Just days after scientific founder Emmanuelle Charpentier shared the Nobel prize for her work on CRISPR/Cas9, CRISPR Therapeutics $CRSP is showing off a snapshot of success in their early-stage study for an off-the-shelf CAR-T approach to CD19+ B cell malignancies — a snapshot marred by the death of a patient who had been given a high dose of the treatment.

Using their gene editing tech, researchers for CRISPR engineered cells from healthy donors into an attack vehicle aimed at cancer, something that has been achieved with great success using patients’ own cells — the autologous approach. But autologous CAR-T is hampered by the more complex vein-to-vein requirement that delays treatment, and now CRISPR Therapeutics along with other players like Allogene are determined to replace the pioneers with CAR-T 2.0.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.

Pur­due Phar­ma signs guilty plea, preps $8B+ set­tle­ment on Oxy con­tro­ver­sy — re­port; Flag­ship brings in a comms chief

Purdue Pharma may soon be signing off on a guilty plea and an $8 million-plus settlement to wrap up its controversial role distributing OxyContin.

The AP has the breaking story this morning.

Purdue filed for bankruptcy last year, along with Insys and followed by Mallinckrodt, as it navigated its way through a blizzard of litigation surrounding Oxy, which triggered an epidemic of abuse around the country.

Covid-19 roundup: FDA has fi­nal­ly post­ed dis­cus­sion items for to­mor­row's ad­comm; As­traZeneca could soon re­sume US vac­cine tri­als

It may have come a day late, but the FDA has finally posted the discussion items that its outside experts will review during tomorrow’s adcomm on the new wave of Covid-19 vaccines now in the clinic.

There are no specific vaccines or data to discuss. Instead, the agency wants feedback on its overall approach. And they’re willing to go late into the evening to get it.

Here’s the rundown:

1. Please discuss FDA’s approach to safety and effectiveness data as outlined in the respective guidance documents.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.

CEO Grace Colón (InCarda)

Look­ing to re­pur­pose an old drug to treat ir­reg­u­lar heart­beats, In­Car­da rais­es $30M in first Se­ries C close

A little less than two years after completing its $42 million Series B round, InCarda has returned to the venture well.

The San Francisco-based biotech announced the first portion of its Series C on Wednesday, pulling in $30 million in new funding. Most of the money will give enough runway for InCarda’s InRhythm program, an inhaled therapeutic aiming to treat sudden episodes of irregular heartbeats, through its Phase II trials and prepare it for Phase III.

Derek Chalmers, Cara Therapeutics CEO

Cara lines up a $440M deal for US rights to its late-stage drug for se­vere itch, with $150M cash on the ta­ble

With plans afoot to file an NDA for what could be its first approved drug, Cara Therapeutics is pivoting its focus to commercialization. And Swiss company Vifor Pharma is willing to surrender up to $440 million to market the candidate in the US.

Cara $CARA CEO Derek Chalmers said an NDA submission is coming this quarter for their intravenous drug Korsuva in chronic kidney disease-associated pruritus (CKD-aP), a severe itching condition. The Stamford, CT-based biotech read out positive topline data from a Phase III pivotal study back in April, and announced plans to approach EMA regulators shortly after filing with the FDA.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.